Company Overview and News
If you look at a typical brokerage summary page for Alexion Pharmaceuticals (ALXN), one thing you might spot is negative earnings for the past year and a negative P/E (price to earnings) ratio. Clinical development stage biotechs often run for years at a loss, generating such figures, but Alexion has been profitable by most measures for years. Here, I will clear up the mystery, arguing that, in this case, non-GAAP numbers are more useful to predicting future profits than GAAP numbers.
Massachusetts in general and Boston, specifically Cambridge, is one of the two largest centers in the U.S. for biotech startups and life science companies (the other being the San Francisco Bay Area). Here’s a look at 13 Massachusetts life science companies that are showing both gains and losses—mostly gains—at the six-month mark.
VRTX BSX ALXN TMO ANIK HBIO
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features updated research reports on 16 major stocks, including Mastercard (MA), AbbVie (ABBV) and Twenty-First Century Fox (FOXA). These research reports have been hand-picked from roughly 70 reports published by our analyst team today.
FOX GD ZTO MA BXP TCO CVS FTV 7018 ALXN AMT CME PPL ABBV FOXA ABBV
Stocks were indicated to higher on Tuesday after Monday’s recovery rally. Investors have seen a very strong earnings season, with 80% of the S&P 500 reporting earnings and over 70% exceeding expectations. That said, the volatility in 2018 has created a less rewarding “buy every dip” than had been seen in prior years. Many investors are also trying to decide how they want their investments positioned ahead of the midterm elections and with international trade concerns.
Z OBSV ILMN SEAS ALXN AMAT AVGO WMB MS ETSY ABX CBS ALKS ABX WYNN PDCE CBS.A PHM NBIX CBS.WD ACAD ZG TRI CPV BRCM ALDR ALNY
Investors with an interest in Medical - Biomedical and Genetics stocks have likely encountered both Alexion Pharmaceuticals (ALXN - Free Report) and Regenxbio (RGNX - Free Report) . But which of these two stocks is more attractive to value investors? We'll need to take a closer look to find out.
ALXN BGSF RGNX
Cellectis – France-based Cellectis named Novartis veteran Stefan Scherto as its new head of clinical development and deputy medical officer. Prior to his role at Cellectis, Scherto served as head of early development of strategy and innovation in U.S. oncology for Novartis. Scherto is expected to play a key role in moving Cellectis’ off-the-shelf gene-edited CAR-T cell product candidates toward commercialization.
ABT ALXN GILD TRVN QSII KITE ABEO ABEOW ABT BCART
A stock at a 52-week high level is perceived a winner. This level works as an indicator for many investors for buying or selling a stock. Quite often, investors start wondering if this level has made a stock an overpriced one. While they are not totally incorrect, all stocks hitting a 52-week high are not necessarily overpriced. In fact, a decision to avoid stocks that are trading near their 52-week high levels makes an investor miss out on most of the top gainers.
COP ALXN ADM NSIT
Nabriva Therapeutics – Nabriva Therapeutics restructured part of its leadership team in the wake of the acquisition of Zavante Therapeutics. Colin Broom, who had served as chief executive officer of Nabriva, was replaced by Zavante CEO Ted Schroeder. Broom will maintain a seat on the board of directors and serve in an advisory role to Schroeder. Steven Gelone, Nabriva's chief scientific officer and head of business & corporate development, has been named president and chief operating officer of Nabriva.
VYGR OPTI ALXN NBRV ABEO ABEOW ARIA OPBXF
NEW HAVEN, Conn. (AP) — In a story Thursday about Alexion Pharmaceuticals Inc.'s quarterly earnings — generated by Automated Insights using data from Zacks Investment Research — The Associated Press reported erroneously that the company is based in New Haven, Connecticut. Alexion has relocated to Boston.
Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION
1h - Asif
Business overview Rennova Health, Inc. (together with its subsidiaries, “Rennova”, “we” or the “Company”) is a provider of an expanding group of health care services for healthcare providers, patients and individuals. Beginning in 2018, the Company intends to focus on and operate two synergistic divisions: 1) Clinical diagnostics through its clinical laboratories; and 2) Hospital operations through its Big South Fork Medical Center, which opened on August 8, 2017, and a hospital in Jamestown Tennessee, including a doctor’s practice, the assets of which the company expect to acquire in the second quarter of 2018, pursuant to the terms of a definitive asset purchase agreement that the company entered into on January 31, 2018, as more fully discussed below. The company believe that its approach will produce a more sustainable business model and the capture of multiple revenue streams from medical providers, patients and hospital services. Management determined that because Big So...
2018-08-13 - Asif
Core Business At Ballard, Ballard Power Systems is building a clean energy growth company. Ballard Power Systems is recognized as a world leader in proton exchange membrane (“PEM”) fuel cell power system development and commercialization. The company's principal business is the design, development, manufacture, sale and service of PEM fuel cell products for a variety of applications, focusing on its power product markets of Heavy-Duty Motive (consisting of bus, truck, rail and marine applications), Portable Power, Material Handling and Backup Power, as well as the delivery of Technology Solutions, including engineering services, technology transfer, and the license and sale of its extensive intellectual property portfolio and fundamental knowledge for a variety of fuel cell applications. A fuel cell is an environmentally clean electrochemical device that combines hydrogen fuel with oxygen (from the air) to produce electricity. The hydrogen fuel can be obtained from natural g...
2018-08-13 - Asif
Overview Marathon Patent Group was incorporated in the State of Nevada on February 23, 2010 under the name Verve Ventures, Inc. On December 7, 2011, the company changed its name to American Strategic Minerals Corporation and were engaged in exploration and potential development of uranium and vanadium minerals business. In June 2012, the company discontinued its minerals business and began to invest in real estate properties in Southern California. In October 2012, the company discontinued its real estate business when its former CEO joined the firm and the company commenced its IP licensing operations, at which time the Company’s name was changed to Marathon Patent Group, Inc. On November 1, 2017, the company entered into a merger agreement with Global Bit Ventures, Inc. (“GBV”), which is focused on mining digital assets. Marathon Patent Group has since purchased its cryptocurrency mining machines and established a data center in Canada to mine digital assets. Following the me...
as of ET